11 research outputs found
Evaluation of a Polymeric Flap Valve-Attached Ureteral Stent for Preventing Vesicoureteral Reflux in Elevated Intravesical Pressure Conditions: A Pilot Study Using a Porcine Model
339 EXPERIENCE OF A DEDICATED METABOLIC CLINIC IN THE MANAGEMENT OF CYSTINE STO NE DISEASE
Pain during transrectal ultrasonography guided prostate biopsy: a randomized prospective trial comparing periprostatic infiltration with lidocaine with the intrarectal instillation of lidocaine-prilocain cream
Prostate biopsy is usually performed without anesthesia. We evaluated
the patient’s perception of pain/discomfort experienced during the
procedure in terms of the type of anesthesia used: periprostatic
infiltration with 2% lidocaine, or intrarectal instillation of
lidocaine-prilocain cream. A total of 198 patients were divided into
three groups: group 1 ( control group, n= 40) received sonographic gel
intrarectally prior to biopsy, group 2 ( n= 75) were given intrarectal
instillation of lidocaine-prilocain cream, and group 3 ( n= 80) received
periprostatic anesthesia by injecting 10 ml of 2% lidocaine. Pain after
each biopsy was assessed using an 11-point linear visual analog pain
scale. The mean pain scores were 5.1 in group 1, 4.8 in group 2, and 2.5
in group 3, resulting in a significant difference between group 3 and
both groups 1 and 2, but not between groups 1 and 2. The incidence of
biopsy-related adverse events did not differ among groups.
Transrectalultrasonographic guided periprostatic anesthesia is superior
to intarectal instillation of lidocaine-prilocain cream
Prevention of recurrent bacterial cystitis by intravesical administration of hyaluronic acid: a pilot study
OBJECTIVES
To assess the effect of bladder instillations of hyaluronic acid (HA) on
the rate of recurrence of urinary tract infection (UTI).
PATIENTS AND METHODS
Forty women (mean age 35 years) with a history of recurrent UTI received
intravesical instillations of HA (40 mg in 50 mL phosphate-buffered
saline) once weekly for 4 weeks then once monthly for 4 months. The UTI
status was assessed over a prospective follow-up of 12.4 months and
compared with the rates of UTI before instillation, determined by a
retrospective review of patient charts covering 15.8 months.
RESULTS
After HA treatment no patients had a UTI during the 5-month treatment
phase and 28 (70%) were recurrence-free at the end of the follow-up.
The mean (SD) rate of UTI per patient-year was 4.3 (1.55) before
treatment and 0.3 (0.55) afterward (P < 0.001). The median time to
recurrence after HA treatment was 498 days, compared with 96 days
beforehand (P < 0.001). The tolerability was excellent, as side-effects
were limited to nine patients who reported mild bladder irritation; no
patient interrupted the treatment.
CONCLUSIONS
In this preliminary study, bladder instillations of HA had a significant
effect on the rate of UTI in women with a history of recurrent UTIs. The
bladder instillation of HA is an acceptable and promising therapeutic
alternative in patients with recurrent UTI. Expanded placebo controlled
clinical trials examining this application of HA are currently underway